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INTRODUCTION
Allogeneic stem cell transplantation (alloHCT) has been the standard of care for medically fit patients with high-risk CLL for almost a decade. The consensus criteria of the European Society for Blood and Marrow Transplantation (EBMT) for the selection of patients with CLL for alloHCT were established in 2007 (ref. 1) . High-risk CLL was defined by disease that required treatment and which harbored a deletion 17p/TP53-mutation, purine analog (PA) refractory disease and relapse within 2 years after intensive chemoimmunotherapy or autologous HCT.
With the advent of alternative treatment options for these high-risk patient groups, the selection of patients for alloHCT became more challenging. Ibrutinib, a BTK-inhibitor, and Idelalisib, a PI3K-inhibitor, were approved in early 2014 in the United States and in late 2014 in Europe. Both drugs are orally available, have a rather good safety profile and demonstrated a survival advantage in randomized controlled trials compared with palliative treatment options. 2, 3 Although none of these drugs induces CR as single agents, their good tolerability and sustained efficacy in maintaining PRs render them very valuable. Moreover, the BCL2-inhibitor venetoclax, another oral drug which demonstrated remarkable activity in patients with del(17p)/TP53 mut CLL, has recently been approved by the United States Food and Drug Administration. 4 The safety and efficacy of combinations with these new drugs and sequential therapies after resistance to either of the new drugs are under investigation. [5] [6] [7] [8] [9] In a recently published position paper from the EBMT and the European Research Initiative for CLL (ERIC) on indications for alloHCT, the authors advocate weighing out the disease-specific risk, patient's preference and the individual risk of transplantationrelated complications when providing counseling for alloHCT. 4, 10 Risk factors for treatment success after alloHCT have so far only been defined in relatively small cohorts of patients with CLL however. [11] [12] [13] We therefore set out to identify baseline risk factors that can predict non-relapse mortality (NRM) and longterm disease control, and thus be useful in advising on therapy.
In order to assess the disease-specific risk of patients with CLL at the time of alloHCT, the EBMT launched a retrospective survey of patients who were transplanted between January 2000 and December 2011. Participating transplant centers provided extensive baseline information and updated outcome data. Here, we report on baseline risk factors for 2-year NRM as indicator of the short-term risk of procedure-related death and 5-year event-free survival (EFS) as a surrogate for long-term disease control.
MATERIALS AND METHODS Approach
Data were extracted from the EBMT registry and upgraded and updated through a Data Quality Initiative (for details see Supplementary Material).
All patients who received a first alloHCT for CLL between January 2000 and December 2011 were eligible for inclusion. Patients were excluded if they had experienced Richter's transformation prior to transplantation, or if they had received cord blood or a graft from a mismatched related or syngeneic donor.
Definitions
Remissions were assessed according to effective guidelines of the International Working Group for CLL.
14,15 PA refractory disease was defined as non-response to PA containing chemotherapy or relapse within 6 months. Patients with re-treatment of CLL within 24 months after PA combination chemotherapy were considered as having early relapse. Patients with a time to re-treatment after the last PA combination therapy of more than 2 years, and patients with a remission duration of more than 6 months after PA monotherapy were considered as having PA-sensitive Abbreviations: alloHCT = allogeneic hematopoietic cell transplantation; autoHCT = autologous hematopoietic cell transplantation; MAC = myeloablative conditioning; NMA = non-myeloablative; PA = purine analog; RIC = reduced-intensity conditioning.
a
The number of patients with available information is given in parentheses if deviating from total number.
Treatment risk factors for CLL transplant patients J Schetelig et al disease. Cytogenetic abnormalities were classed hierarchically according to Döhner et al. 16 Conditioning intensity was classified according to the working definitions published by Bacigalupo et al. 17 Donor type was classified according to the definition of Weisdorf et al. 18 
Statistical analysis
The primary goal of this analysis was to identify risk factors for NRM within the first 2 years and estimate the magnitude of their effect. We selected 2 years as a time horizon because treatment-related mortality mainly occurs within the first 2 years. Furthermore, 2-year outcomes can easily be compared with results of targeted therapies with currently limited followup. In addition, EFS up to 5 years after alloHCT was analyzed as a surrogate for long-term disease control.
EFS was calculated as time to death, relapse or disease progression, whichever occurred first, with patients surviving relapse/progression-free censored at the time of last follow-up. Secondary analyses dealt with overall survival (OS) and the cumulative incidence of relapse or progression (CIR). CIR or progression and NRM were analyzed as competing end points. EFS and OS for the whole cohort and subgroups were analyzed by means of the Kaplan-Meier method and compared by a log-rank test, CIR and NRM by means of cumulative incidence functions and compared by using a Gray's test.
Cox regression models for (cause-specific) hazards were fitted for the respective end points to evaluate a potential clinical impact of risk factors on transplant outcomes. Our objective was to get an overview of the most relevant risk factors and to find their optimal estimate in order to better understand their impact on transplant outcome. Therefore we did not aim for the most parsimonious models or for models optimized for prediction for new patients. To account for missing information for some risk factors we used multiple imputation. 19 Age, donor type and donor-recipient sex match were entered into all models reflecting their use in the EBMT risk score. Next, we applied a selection procedure among the following baseline variables: year of alloHCT, Karnofsky Index, worst Binet stage, cytogenetic abnormalities, remission status, chemotherapy sensitivity, PA sensitivity, treatment with alemtuzumab prior to start of conditioning regimen, number of lines of pre-treatment, history of prior autologous HCT, donor-recipient CMV match, graft type, conditioning regimen and type of T-cell depletion. With the goal of showing the relevance of the fitted models for separating outcomes of patients with favorable and unfavorable characteristics, we plotted the model-based predicted probabilities for a set of representative reference patients. For this purpose we selected good-and poor-risk male and female reference patients in such a way that the risk scores for the EFS model for the male patients were close to the 10th and the 90th percentile in one MI data set. All analyses were performed in SPSS Version 21 and R 3.1.0 (IBM corporation, Armonk, NY, USA) using the packages 'mice', 'survival', 'mstate' and 'cmprsk'. 20 Further details on the statistical analyses are given in the Supplementary Material.
RESULTS

Transplant activity
Thirty-two centers contributed data. In total, data on 694 patients met the selection criteria for this analysis. (5) 52 (6) 52 (6) 42 (6) 29 (5) 37 (6) 19 (5) 21 (5) Age ⩾ 45 to o55 yrs 256 70 (3) 56 (4) 56 (3) 44 (3) 23 (3) 29 (3) 21 (3) 27 (3) Age ⩾ 55 to o65 yrs 309 57 (3) 40 (3) 49 (3) 33 (3) 15 (2) 24 (3) 36 (3) 44 (3) Age ⩾ 65 yrs 49 59 (7) 25 (9) 48 (7) 17 (7) 20 (6) 31 (8) 32 (7) 52 (9) Karnofsky 100% 186 68 (4) 52 (4) 57 (4) 41 (4) 18 (3) 28 (4) 25 (3) 30 (4) Karnofsky 90% 307 67 (3) 47 (3) 56 (3) 37 (3) 18 (2) 28 (3) 26 (3) 35 (3) Karnofsky 80% 113 55 (5) 40 (5) 38 (5) 32 (5) 24 (4) 27 (5) 37 (5) 42 (5) Karnofsky ⩽ 70% 25 34 (10) 29 (10) 28 (9) 23 (9) 31 (10) 31 (10) 41 (10) 46 (11) PA-refractory CLL 245 62 (3) 44 (4) 50 (3) 32 (4) 23 (3) 32 (3) 27 (3) 36 (4) PA-sensitive CLL 159 70 (4) 52 (4) 61 (4) 45 (4) 13 (3) 21 (3) 26 (4) 33 (4) Cytogenetics del(17p) 144 56 (5) 37 (5) 47 (5) 33 (5) 23 (4) 28 (4) 30 (4) 39 (5) del(11q)/no del(17p) 142 68 (4) 49 (5) 53 (4) 34 (5) 20 (4) 31 (4) 27 (4) 35 (4) Other abnormalities 166 67 (4) 49 (4) 56 (4) 39 (4) 17 (3) 27 (4) 26 (4) 34 (4) No abnormalities 71 72 (5) 62 (6) 63 (6) 50 (6) 14 (4) 22 (5) 23 (5) 28 (6) CR at alloHCT 84 67 (5) 57 (6) 66 (5) 50 (7) 4 (2) 12 (4) 30 (5) 38 (6) PR at alloHCT 344 67 (3) 50 (3) 55 (3) 40 (3) 20 (2) 28 (3) 25 (2) 32 (3) SD/PD at alloHCT 224 58 (3) 40 (4) 42 (3) 29 (3) 27 (3) 34 (3) 31 (3) 37 (3) HLA-identical SIB 283 70 (3) 53 (3) 56 (3) 43 (3) 22 (3) 31 (3) 22 (3) 26 (3) Matched UD 327 61 (3) 45 (3) 51 (3) 35 (3) 19 (2) 25 (3) 30 (3) 40 (3) Partially mUD 84 52 (6) 31 (7) 43 (6) 24 (6) 17 (4) 25 (5) 41 (6) 51 (6) Abbreviations: alloHCT = allogeneic hematopoietic cell transplantation; mUD = matched unrelated donor; N = number of patients; PA = purine analog; PD = progressive disease; SD = stable disease; SIB = sibling; UD = unrelated donor; yrs = years.
Treatment risk factors for CLL transplant patients J Schetelig et al of patients had a Karnofsky Index of 90% or higher. Only 4% of patients were unable to work or care for their own personal needs. Poor performance status was associated with uncontrolled disease at the time of alloHCT (P o0.001). Seventy percent of patients with a Karnofsky Index ⩽ 70% had stable or progressive disease (SD/PD) at alloHCT compared with only 29% of patients with a Karnofsky Index of 90%. Only 9% of patients had never received purine-analogs during their treatment history. A deletion 17p had been diagnosed in 28% of patients. Seventy-six percent of patients met EBMT consensus indications.
Outcomes for the whole cohort of patients For the whole cohort of patients, OS, EFS, CIR and NRM are shown in Table 2 and Figure 1 . Median follow-up of surviving patients was 41 months (range 1-147 months). The probability of EFS at 2 years was 52% (95% confidence interval (CI), 48-56%) and decreased to 25% (95% CI, 19-31%) at 10 years. OS decreased from 64% (95% CI, 60-67%) at 2 years to 34% (95% CI, 28-40%) at 10 years. NRM dominated over CIR as cause of failure up to 2 years after alloHCT. The probability of NRM was 28% (95% CI, 25-32%) at 2 years and 35% (95% CI, 31-39%) at 5 years after alloHCT. CIR/ progression was 20% (95% CI, 17-23%) at 2 years and 28% (95% CI, 24-31%) at 5 years after alloHCT.
As the patients whose registry data were reviewed for the Data Quality Initiative represent a subset of all EBMT-registered patients with CLL, we compared point estimates for OS, EFS, NRM and CIR of both data sets. No significant differences were found.
Univariate analyses of subgroups of patients In univariate comparisons, the 5-year EFS rate was better in patients transplanted with PA-sensitive disease compared with PA-refractory disease (45% versus 32%, P = 0.03). This difference was largely caused by a higher CIR in patients with PA-refractory CLL (32% versus 21%, P = 0.06). Notably, 48% of patients with PArefractory CLL had SD/PD at alloHCT compared to 27% of patients with PA-sensitive CLL.
The 5-year EFS-probability was 29% in patients with SD/PD and 40% in patients with PR at alloHCT (P = 0.002). Sixteen percent (95%CI, 8-25%) of patients with SD/PD were event-free at 10 years post alloHCT. This result indicates that a small group of patients with SD/PD achieves long-term disease control with alloHCT.
Data on 49 patients with an age of 65 years or more were in the analysis. The 5-year EFS was lower compared with 80 patients transplanted at an age below 45 years of age (17% versus 42%, P = 0.15). Poorer outcome of elderly patients was due to higher NRM up to 5 years post alloHCT (52% versus 21%, P = 0.007).
Results of multivariate analyses Two-year non-relapse mortality and incidence of relapse/progression. Four risk factors had a significant negative impact on NRM: higher age, reduced performance status, HLA disparity and unfavorable donor-recipient sex match (Table 3A) . As for the donor-recipient sex constellation, HCTs of patients who had donors of the same sex had the lowest risk of NRM. Male patients with female donors had a significantly higher risk of NRM. Apart from performance status, other disease or treatment history-related factors had no significant impact on NRM. Two factors had a significant impact on relapse/progression within the first 2 years after alloHCT: prior autologous HCT and remission status at alloHCT. Impact of Karnofsky Index, cytogenetics, PA sensitivity, pre-treatment with alemtuzumab and donor-patient sex match was borderline significant. Compared with patients with 17p-CLL patients with cytogenetic abnormalities other than del(17p)/del(11q) had a significantly lower risk of relapse/progression.
Next, we set out to demonstrate the impact of combinations of risk factors on 2-year NRM. Four reference patients were designed such that the characteristics of the whole cohort were wellrepresented. The reference patients differed with respect to age, their Karnofsky performance Index, remission status at alloHCT and donor type and donor sex. All procedure-related factors were fixed to be able to focus on the impact of patient-related factors (for details see Figure 2 legend). The good-risk male reference patient was 45 years of age, had a Karnofsky performance Index of 100%, was in PR at alloHCT and had a matched related male donor. The poor-risk male reference patient was 55 years of age, had a Karnofsky performance Index of 80%, SD/PD at alloHCT and a matched unrelated female donor. The female reference patients shared the same characteristics, apart from the patient and donor sex. Their outcomes were based on the same models. The plots for NRM and CIR in Figure 2 represent the model-based predictions for reference patients with such characteristics. For the good-risk male patient, the predicted cumulative incidence of NRM and CIR within the first 2 years was 11% (95% CI, 7-16%) and 27% (95% CI, 12-41%), respectively. In contrast, for the poor-risk male patient the predicted cumulative incidence of NRM and CIR within the first 2 years was 42% (95% CI, 26-57%) and 26% (95% CI, 9-43%), respectively. Corresponding numbers for the good-risk female reference patient were 12% (95% CI, 6-19%) and 14% (95% CI, 3-26%), and for the poor-risk female reference patient 33% (95% CI, 19-48%) and 17% (95% CI, 3-31%), respectively.
Five-year event-free and overall survival. Five-year EFS was analyzed as a surrogate for long-term disease control. Five risk factors had a significant impact on 5-year EFS: age, performance status, prior autologous HCT, remission status at alloHCT and the donor-patient sex constellation (Table 3A) . Among the correlated risk factors describing the leukemia risk profile, the remission status at alloHCT remained in the final multivariable model, but cytogenetic risk groups and sensitivity to chemotherapy were not retained. The number of lines of previous treatment regimens and therapy with alemtuzumab in the treatment history of CLL did not correlate with outcome. However, prior autologous HCT was a strong negative risk factor. Outcomes for groups of patients with different risk scores were far apart (Supplementary Figure S1) . Again, EFS was predicted for good and poor-risk reference patients with the same characteristics as specified above (Figure 3 ). Predicted 5-year EFS of the good-risk male reference patient was 55% (95% CI, 45-66%) and 15% (95% CI, 6-35%)
for the poor-risk male reference patient. Corresponding numbers for the good-and poor-risk female reference patients were 64% (95% CI, 53-78%) and 30% (95% CI, 17-52%), respectively. Most risk factors had a comparable impact on 5-year EFS and OS, respectively. Overall cytogenetics did not impact on OS significantly (P = 0.13) but the data showed a trend for a higher risk of mortality of patients with a del(17p). However, in univariate analysis, EFS up to 8 years after alloHCT was comparable in patients with deletion(17p) (28%, 95% CI, 18-39%) and without (33%, 95% CI, 27-39%).
DISCUSSION
The number of studies aimed at predicting the outcome of CLL patients after alloHCT is limited. [11] [12] [13] Results indicate that cytogenetic risk did not impact on survival, whereas disease activity and/or tumor load were relevant risk factors. Comorbidity was shown to have a major impact on outcome after alloHCT also in CLL. 11 Well-matched unrelated donor HCT was not inferior to HLA-identical sibling transplantation in terms of NRM, EFS and Table 3A . Risk factors for non-relapse mortality, relapse/progression and event-free survival within the first 2 years after allogeneic HCT in patients with CLL
Risk factors
Non-relapse mortality up to 2 years Abbreviations: alloHCT = allogeneic hematopoietic cell transplantation; CI = confidence interval; Del = deletion; HCT = hematopoietic cell transplantation; HR = hazard ratio; PA = purine analog; PD = progressive disease; SD = stable disease; UD = unrelated donor. *Early relapse is defined as re-treatment within 24 months after a purine analog combination therapy; Effect estimates were adjusted for year of transplant, conditioning intensity and T-cell depletion when these procedure-related factors were included in the final model for the respective end point. Hazard ratios and their CIs and P-values are based on multivariate Cox regression models.
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OS in one registry-based analysis, although the small number of patients with well-matched unrelated donors limited the power to detect small differences in these outcomes. 21 Here, we report results of the largest comprehensive risk factor analysis so far. On the basis of the results we can describe patients with distinct combinations of risk factors with very different risk of NRM and long-term disease control. Two-year NRM differed by 30% and 5-year EFS by 40% between male reference patients who represent favorable and unfavorable characteristics in this data set well (Figures 2 and 3) . We did not specifically study the impact of center characteristics in this study. Such factors could further increase variation in outcomes. However, the magnitude of difference for NRM and EFS explained by patient baseline characteristics alone is remarkable.
In line with other large studies this analysis demonstrated a significant impact of performance status and age on 5-year EFS/ OS and 2-year NRM. 13, 21, 22 Interestingly, performance status had a bigger impact on CIR than on NRM. This pattern has been reported before in patients with CLL and is consistent with the concept that the performance status is mainly determined by the disease activity. 23, 24 Moreover, it could reflect selection of patients with very aggressive disease for alloHCT.
We show that unrelated donor HCT was still associated with a higher risk of NRM, especially in the HLA-mismatch situation. Remarkably, a female-to-male (F → M) sex-mismatch had a significant impact on 5-year EFS/OS as well as on 2-year NRM in this data set. Female donor-derived cytotoxic T lymphocytes can recognize male minor histocompatibility Ag-peptide complexes presented by HLA-class one molecules. 25 These effector cells can cause GvHD but also contribute to GvL reactions. 26 A net negative effect of the F → M sex-mismatch has been reported in many but not all studies. 27 The net effect of this factor varies between diseases and could be dependent on donor type and procedurerelated issues. 22 Moreover, in our study, the sex of the patients itself also seemed to contribute to the difference in outcomes. When discussing chances and risks of alloHCT and alternative treatments with individual patients, a given HLA-mismatch or unfavorable sex match can be used as arguments to favor alternative options if available.
Current knowledge suggests that alloHCT can overcome the negative prognostic impact of high-risk cytogenetic abnormalities, especially of a deletion(17p) or TP53-mutation (del(17p)/ TP53 mut ). 1, 10, 11, 28 However, even in the largest study only data from 28 patients with del(17p)/TP53 mut were compared to Figure 2 . Model-based prediction of non-relapse mortality and relapse/progression within the first 2 years after alloHCT. The good-risk male reference patient has an age of 45 years, a Karnofsky performance Index of 100%, is in PR at alloHCT and has a matched related male donor. The poor-risk male reference patient has 55 years of age, a Karnofsky performance Index of 80%, SD/PD at alloHCT, and a matched unrelated female donor. The remaining baseline risk factors are set at no prior autologous HCT, cytogenetic abnormalities other than del(17p) or del (11q), purine analog refractory disease, no alemtuzumab during pre-treatment, NMA as conditioning, no T-cell depletion and transplantation in 2006. The risk scores of the good-and poor-risk reference patient are located at the 3rd and 90th percentile of all observed risk scores in one imputed data set. The female reference patient has the same characteristics, apart from the patient and donor sex: the good-risk patient has a female donor, the poor-risk patient a male donor. Their risk scores are located at the 3rd and 74th percentile, respectively.
controls. 29 We observed a trend for a lower incidence of relapse or progression for patients without del(17p) within the first 2 years after alloHCT, which translated into better EFS. The impact on long-term disease control and mortality was small. Brown et al. 13, 30 also reported an impact of adverse cytogenetic risk on early transplant outcome, which could not be confirmed after longterm follow-up.
Remission status at alloHCT is an important risk factor. As in other studies, patients whose CLL was not in remission had worse short-and long-term disease control also after alloHCT. Remarkably, whether a patient was in CR versus PR had a significant impact on CIR and EFS within the first 2 years but not on 5-year OS. The fact that the response category 'PR' covers fundamentally different levels of residual tumor load ranging from minimal amounts of tumor cells to tumor bulk has to be taken into account when interpreting this finding. Even more surprisingly, while remission status had a dramatic impact on 2-year CIR (hazard ratio 5.2, P = 0.005) it had no significant impact on 5-year OS (hazard ratio 1.1, P = 0.8). Notably, researchers from the Dana Farber Cancer Institute (DFCI) also found factors that reflect chemotherapy sensitivity and tumor load to be relevant: SD/PD versus PR/CR, high LDH and lymphocyte counts 41000/μL. 13 In contrast Sorror et al. 11 found that only the HCT-CI and bulky lymphadenopathy ⩾ 5 cm but not disease response was predictive for long-term EFS and OS. 11 Careful interpretation of the available data therefore suggests that the large group of patients with SD/PD at alloHCT, which represented 34% in this study, might benefit most from access to pathway inhibitors such as ibrutinib, idelalisib or venetoclax prior to alloHCT. The percentage of patients who will proceed to alloHCT among those who are originally scheduled for alloHCT might be higher with the use of pathway inhibitors than with conventional chemotherapy as bridging prior to alloHCT. 31 Yet, information on the use of pathway inhibitors for remission induction prior to alloHCT is still very preliminary and optimally 'intention-to-transplant' trials with these new drugs are warranted.
Ibrutinib and idelalisib represent attractive treatment alternatives for medically fit patients with high-risk CLL for whom alloHCT was recommended before the approval of these drugs. 32 Although desirable, results from randomized trials which provide guidance for the selection of patients for alloHCT cannot be expected. After failure of these targeted drugs, alloHCT will still remain the preferred treatment option. Moreover, our results could be instrumental for the selection of some patients for alloHCT with expected low early NRM who have a remission or stable disease on these drugs. Notably, outcomes of patients who proceeded to alloHCT in remission on treatment with ibrutinib or idelalisib have not been published so far and thus special attention is warranted with this sequence of treatments.
The strengths of this study are its size and the access to comprehensive information on disease-specific risk factors, which was collected within a Data Quality Initiative of the EBMT. Owing to the retrospective nature of the study, a few limitations should be noted. The data do not rely on standardized diagnostic tests and importantly, data on patient comorbidity at baseline were not available. Further, this data set reflects the era of transplantation before pathway inhibitors became available for the treatment of patients with CLL. These drugs may be used prior to alloHCT but also for the treatment of relapse after alloHCT and clearly they have the potential to improve outcome also after transplantation. 33 The level to which NRM is acceptable will also in future depend on the availability, safety and efficacy of alternative treatment options. With respect to ibrutinib, OS and EFS were 79 and 69% in patients with relapsed/refractory CLL at 30 months from the start of the drug. 34 For patients with del(17p) the corresponding figures were 65 and 48%. Thirteen percent of patients died on study, defined as within 30 days of last dose of ibrutinib. In a recent phase II study on venetoclax monotherapy in patients with relapsed/refractory CLL harboring del(17p), PFS at 12 months was 72%. 5 Although the mostly elderly patient populations of these trials cannot be compared with patients who are eligible for alloHCT, the follow-up data suggest that long-term disease control cannot be expected with these agents.
Good results with respect to long-term EFS after alloHCT can be achieved in patients who are in remission and have a good performance status. Yet, these patients will feel the least pressure to accept the risk of NRM even though alloHCT offers hope for a cure. The question whether transplantation can be postponed to the next relapse or progression without a major reduction in chances for long-term success has been reviewed recently. 10 Individual decisions have to be made based on changing grounds. Preclinical data on combination therapies of ibrutinib and venetoclax look very promising so that long-term disease control without alloHCT is also not out of view. 35 Moreover, secondgeneration BTK-inhibitors are entering advanced phases of clinical development (NCT02477696). 36, 37 Further, the fact that BTK-, PI3K-and BCL2-inhibitors target different signaling pathways, raises hope that cross-resistance will not be a common theme. 8, 38 However, available clinical data on responses after failure of ibrutinib or idelalisib are still preliminary. 5, 6 In conclusion, this study adds information on risk factors for alloHCT in patients with high-risk CLL. These factors allow the identification of patients with a good chance of long-term disease control despite high-risk CLL. It is likely, more effective induction regimens prior to, and better salvage regimens after, alloHCT will improve future results in these groups of patients. On the other hand, we identified groups of patients with a high risk of NRM Figure 3 . Model-based prediction of 5-year event-free survival. Cox model-based plots for event-free survival in reference patients. As in Figure 2 , the good-risk male reference patient (solid black curve) has an age of 45 years, a Karnofsky performance Index of 100%, a PR and a matched related male donor. The poor-risk male reference patient (dashed red curve) is 55 years old, has a Karnofsky performance Index of 80%, stable or progressive disease at alloHCT and a matched unrelated female donor. Neither had experienced prior autologous HCT; both had NMA as conditioning and no T-cell depletion. The risk scores of the good-and poor-risk reference patients are located at the 13th and 92nd percentile of all observed risk scores in one imputed data set. The female reference patients had the same characteristics, apart from the patient and donor sex: the good-risk female patient (dashed black line) has a female donor, the poor-risk female patient (dashed red line) a male donor. Their risk scores are located at the 3rd and 72nd percentile, respectively.
based on simple risk factors such as age, performance status, donor type and donor sex. Clearly, patients with a risk of NRM of 20% or more within the first 2 years after alloHCT who have alternative safe treatment options should take advantage of them. Abbreviations: alloHCT = allogeneic hematopoietic cell transplantation; CI = confidence interval; Del = deletion; HCT = hematopoietic cell transplantation; HR = hazard ratio; UD = unrelated donor. Effect estimates were adjusted for conditioning intensity and T-cell depletion when these procedure-related factors were included in the final model for the respective end point. Hazard ratios and their CIs and P-values are based on multivariate Cox regression models.
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